A new wave of antitrust legislation is gathering momentum in Congress, with multiple bills specifically targeting private equity consolidation in healthcare. The legislative push reflects growing bipartisan concern about the effects of PE-driven roll-ups on healthcare costs, access, and quality across hospitals, physician practices, dental organizations, and other care settings. The bills would impose new disclosure requirements, strengthen FTC enforcement authority, and in some cases create outright restrictions on certain PE healthcare transactions.

Congressional interest in PE healthcare consolidation has been building since the Steward Health Care bankruptcy (covered separately in today's briefing) and a series of high-profile academic studies linking PE ownership to higher patient costs and, in some cases, worse outcomes. The FTC under Chair Lina Khan's successor has continued aggressive scrutiny of healthcare mergers, but enforcement alone has proven insufficient — deals structured as management service agreements (MSOs) often fall below merger notification thresholds. These new bills aim to close that gap by expanding the definition of reportable transactions to include MSO arrangements, joint ventures, and other structures commonly used in dental and physician practice consolidation.

For the dental industry, this legislation could fundamentally alter the DSO transaction landscape. Many DSO acquisitions are structured through MSO agreements specifically to avoid triggering Hart-Scott-Rodino antitrust filing requirements. If new legislation requires disclosure and review of MSO transactions, deal timelines could lengthen significantly, transaction costs would increase, and some deals might face regulatory challenge. PE firms considering dental platform investments would need to factor in regulatory risk that barely existed two years ago. For independent practices considering affiliation or sale, expanded antitrust scrutiny could slow the deal pipeline and potentially affect valuations if buyer competition decreases.

Watch for which specific bills gain committee traction and whether the bipartisan energy translates into actual floor votes. Key provisions to monitor: MSO disclosure requirements, FTC enforcement funding, state attorney general empowerment provisions, and any carve-outs for smaller transactions. The dental lobby — including the ADA and state dental associations — has generally supported antitrust enforcement against insurance consolidation but has been more nuanced on provider-side consolidation. How organized dentistry positions itself on these bills will signal whether the profession views DSO consolidation as a market efficiency or a competitive threat.